VP, I&N/CV VP Medical Early Differentiation and Pipeline

Working with Us
Challenging. Meaningful. Life-changing. Those aren’t words that are usually associated with a job. But working at Bristol Myers Squibb is anything but usual. Here, uniquely interesting work happens every day, in every department. From optimizing a production line to the latest breakthroughs in cell therapy, this is work that transforms the lives of patients, and the careers of those who do it. You’ll get the chance to grow and thrive through opportunities uncommon in scale and scope, alongside high-achieving teams rich in diversity. Take your career farther than you thought possible.

Bristol Myers Squibb recognizes the importance of balance and flexibility in our work environment. We offer a wide variety of competitive benefits, services and programs that provide our employees with the resources to pursue their goals, both at work and in their personal lives. Read more: careers.bms.com/working-with-us.

VP, I&N/CV VP Medical Early Differentiation and Pipeline

ROLE SUMMARY

Leader of I&N/CV Medical VP Medical Early Differentiation and Pipeline will lead a team to provide early and ongoing medical input across all Therapy Portfolios to drive clinical differentiation and maximize health outcomes, early clinical adoption and patient access across three BMS Asset Therapy areas.  The goal of this function is to expand the clinical value and patient reach of the early portfolio assets.

This is a senior medical leadership role reporting to the VP Medical Early Differentiation and Pipeline of and will be a member of their Leadership Team.

Location:  New Jersey

Responsibilities:
Accountable for leading a team of senior medical affairs professionals focusing on BMS’ early pipeline that ensures optimal differentiation, access, and proof of concepts for our early pipeline – expanding the value of the early pipeline

• Responsible for shaping the early portfolio narrative and communicating its strategy internally and externally. Leverage knowledge of the medical landscape including a strong understanding of medical affairs strategies and tactics for early phase clinical assets.
• Inform and accelerate governance decisions on priority programs.
• Make recommendation to research and clinical development teams on based external landscape and insights from scientific partnerships and external experts.
• Understand an integrated approach to differentiating drug therapies including enhancing the future value proposition to patients, HCPs, and payers worldwide.  
• Form early scientific partnerships, councils and research collaborations at top centers of excellence for research and with patients when applicable
• Leverage an understanding of anticipated changes in Policy/Payor/Clinic models in US, and EU, Japan, Asia and LatAm, to guide development strategies.
• Represent medical perspective in business development.
• Understand the role of correlative assays and diagnostic platforms in determining treatments across diseases of interest and integrate this understanding into early program strategic approaches.
• Ensure that execution of a comprehensive medical communications plan (including publication planning) is integrated into priority asset plans.
• Identify and execute opportunities for medical affairs enabled signal generation for priority assets, leveraging internal organization as well as external trusted centers of excellence.
• Leverage novel approaches to integrating patient journey insights into early compound differentiation strategies.

In this role you will:

• Focus on early pipeline, namely assets in Phase 1 and Phase 2 signal seeking development.
• Lead a team of senior medical affairs professionals to ensure the development and execution of strategies that drive clinical differentiation and ensure successful fit to clinic.
• Work across Therapeutic Area Franchises (Immunology/Neurology, Cardiovascular) with tailored approaches to each market.
• Bring a patient lens and perspective to early development and ensure plans are reviewed with external stakeholders.
• Provide leadership in relation to biomarkers and CDx as well as potential clinical applicability/utility.
• Leverage an understanding of anticipated changes in Policy/Payor/Clinic models in US, and EU, Japan, Asia and LatAm, to guide strategies.
• Enhance the differentiated clinical value and leadership of our early portfolio, by shaping the design and implementation of innovative biomarker, diagnostic test, diagnostic platform, software and big data solutions and strategic collaborations.
• Partner with Therapeutic Area teams to align early pipeline strategies with TA strategies.